Limerick, PA – Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technology products, today announced that its VasoNova Inc. subsidiary has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the company’s VPS™ peripherally inserted central catheter tip location technology as an alternative to chest x-ray or fluoroscopy in adult patients when the guidance indicator shows a blue bullseye.

Currently, after most central venous catheters are placed, the correct location of the implanted catheter needs to be confirmed by chest x-ray, a process that is costly, time consuming, often repeated because of inaccuracy and which exposes the patient to radiation.

“VasoNova’s VPS™ system is a market-leading central venous catheter navigation technology. This clearance puts us in a strong competitive position and offers the potential to establish a new standard of care in catheter placement,” commented Benson Smith, Teleflex Chairman, President and CEO.

VasoNova VPS™ is the first system to use a combination of hemodynamic and other biometric data to calculate precise tip location and to communicate the position to the user via a simple graphical interface. The system provides the clinician with the opportunity to place the catheter correctly the first time, avoiding the need for confirmatory chest x-ray where indicated. This provides benefits to the patient, the care-giver and the health care system as a whole.

The VasoNova VPS™ system, comprising a portable console and a single-use bio-sensor that is compatible with all major makes of central venous catheters, is available now. The company began shipping product in January to hospitals in the United States.

About Teleflex Incorporated

Teleflex Incorporated (NYSE: TFX) is a global provider of medical technology products that enable healthcare providers to improve patient outcomes, protect against infections and support patient and provider safety. Teleflex, which employs approximately 12,500 people worldwide, also has niche businesses that serve segments of the aerospace and commercial markets with specialty engineered products. Additional information about Teleflex can be obtained from the company’s website at www.teleflex.com.

Forward-looking information

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Limerick, PA – Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technology products, today announced it has acquired privately-held VasoNova Inc. in a transaction valued at up to $55 million.

Based in Menlo Park, CA, VasoNova has developed a unique central venous catheter navigation technology that allows for real-time accurate confirmation of placement of peripherally inserted central catheters and central venous catheters in the lower one third of the superior vena cava, the optimal position for catheter tip location.

“The addition of VasoNova’s technology allows Teleflex to expand our vascular access product offerings and add real-time catheter tip positioning capability to our portfolio that is designed to permit clinicians to confirm central venous catheter location potentially without the need for an X-ray,” said Jeffrey P. Black, Chairman and Chief Executive Officer of Teleflex. “We welcome the VasoNova employees to the Teleflex family and look forward to working with them to expand the presence of VasoNova’s technology in the marketplace.”

Paul Molloy, President and Chief Executive Officer of VasoNova added, “VasoNova’s VPS™ technology is the first real-time intra-vascular catheter navigation technology that does not require external metal detectors or viewing screens, nor subjective interpretation of ECG signals. The combination of the VasoNova™ VPS™ technology and Teleflex’s world-class vascular access product offerings are highly synergistic.”

Under the terms of the agreement, Teleflex has acquired VasoNova for an upfront payment of $25 million and will make additional payments of between $15 million and $30 million based upon the achievement of certain regulatory and revenue targets over the next three years. The combination with VasoNova is expected to be accretive to both revenue and earnings by year-end 2011. Teleflex will report the VasoNova business as part of the vascular access product line in its Critical Care division.

About Teleflex Incorporated
Teleflex is a global provider of medical technology products that enable healthcare providers to improve patient outcomes, reduce infections and support patient and provider safety. Teleflex, which employs approximately 12,800 people worldwide, also has niche businesses that serve segments of the aerospace and commercial markets with specialty engineered products. Additional information about Teleflex can be obtained from the company’s website at www.teleflex.com.

Simpson Thacher & Bartlett LLP provided legal services to Teleflex.

About Vasonova
VasoNova is a privately held company based in Menlo Park, California. Vasonova’s VPS™ technology is the first real time intra-vascular catheter navigation technology that does not require external metal detectors or viewing screens, nor subjective interpretation of ECG signals, and is capable of confirming precise catheter tip location using sophisticated anatomical location identification algorithms embedded in its technology. These location signatures are identified utilizing highly specific Doppler ultrasound characteristics combined with other patient data. VPS™ is compatible with all commonly used PICC and CVC catheters.

Investors include CMEA Capital; California Technology Ventures LLC; Research Corporation Technologies; Arboretum Ventures; Aphelion Capital and Coronis Medical Ventures LLC. Gravitas Healthcare LLC acted as financial advisor and Wilson Sonsini Goodrich & Rosati provided legal services to VasoNova.

Forward-looking information
This press release contains forward-looking statements, including, but not limited to, statements relating to our ability to expand VasoNova’s technology in the marketplace and our expectation that VasoNova will be accretive to both our revenue and earnings results by year-end 2011. Actual results could differ materially from those in the forward-looking statements due to, among other things, conditions in the end markets we serve; customer reaction to the acquisition; unanticipated difficulties, expenditures and delays in complying with government regulations applicable to our businesses, including unanticipated delays, costs and difficulties in connection with obtaining 510(k) clearance from the FDA to expand the uses for which VasoNova’s products may be marketed; changes in the reimbursement practices of third party payors; the impact of government healthcare reform legislation; changes in general and international economic conditions; and other factors described in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Having just secured two more Food and Drug Administration device clearances, VasoNova Inc. says it will launch its vascular navigation system this summer as it mulls a Series C round for commercialization. Sunnyvale, Calif.-based VasoNova has been operating largely in stealth while developing the Vascular Positioning System, a device using Doppler ultrasound and electrocardiography technology for the precise placement of peripherally inserted central catheters, or PICCs.

Chief Executive Gary Wright said the company received two 510(k) clearances this week on catheters and received another catheter clearance, as well as one for its console and stylet, last month.

Working off of the proceeds of a $10 million Series B from August 2008 from Aphelion Capital, Arboretum Ventures, California Technology Ventures, CMEA Ventures, Coronis Medical Ventures, Life Science Angels and Research Corp. Technologies, VasoNova is planning to begin sales in August or September, Wright said. “We raised the money for the R&D associated with the product, which has to do with the algorithms and getting geared up to go to market,” he said.

Wright said the company’s main competitor is publicly traded C.R. Bard Inc., which uses a magnetic-based placement system. “Ours is a physiologic monitoring device. We’re looking at the speed and flow of the blood,” he said. “The majority of PICCs are placed by nurses now that the procedure has moved from the lab to the bedside,” Wright said, highlighting the need for more sophisticated technology to allow for the proper placement of the devices. He also said unguided systems allow for only 74% first-time correct placement, while VasoNova’s is reliable 90% of the time. Wright said VasoNova has enough cash for the initial roll-out but will likely need more money by the beginning of 2010.

VasoNova previously raised $3.85 million in Series A financing in several tranches. The company has 18 full-time equivalent employees.

Sunnyvale, CA – September 16, 2008 – VasoNova, Inc., the leader in algorithm-based vascular navigation and measurement technology, has raised $10 million dollars in Series B funding in August 2008 from venture investors. The round was led by CMEA Ventures. Other investors included California Technology Partners, Research Corporation Technologies, Aphelion Medical Fund and Arboretum Ventures.

The funds will be used to expand market development and customer acquisition, scale product development, and build the customer support and service infrastructure in preparation for product launch in the US market.

About CMEA

CMEA Capital is a venture capital firm focusing on life sciences, high technology, and energy and materials investments. CMEA Capital was founded in 1989. They invest in both early and late stage science-focused ventures, and leverage a strong network of corporate, investment, and entrepreneurial relationships on behalf of portfolio companies. CMEA has offices in both San Francisco and Menlo Park. For more information, see www.cmea.com.

About VasoNova

VasoNova, Inc. has created, developed and commercialized an innovative vascular navigation system. Founded in 2005, VasoNova is the leader in algorithm-based vascular navigation and measurement technology, committed to innovating high quality medical devices to help clinicians address patient needs and improve patient care. VasoNova is located in Sunnyvale, CA. For more information, point your browser to www.vasonova.com.

Training

Please contact your sales representative, VasoNova Customer Service at 650.388.5600 or info@vasonova.com for more information.